SEC Form 4 · accession 0000950138-17-000748
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael-Bryant Hicks
Officer — General Counsel
Period of report
Nov 9, 2017
Accepted (ET)
Nov 13, 2017 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Nov 9, 2017 | P | 7,900 | $20.7986 | A | 16,809 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 530 shares acquired between January 1, 2017 and September 30, 2017 under the Mallinckrodt employee stock purchase plan.